Liposome encapsulated albumin-paclitaxel nanoparticle for enhanced antitumor efficacy

Pharmaceutical Research

Volumn 32, Issue 3, 2015, Pages 1002-1016

  Ruttala, Hima Bindu ^a   Ko, Young Tag ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

albumin nanoparticle; colloidal stability; liposome; paclitaxel; pharmacokinetic

Indexed keywords

ALBUMIN; ALBUMIN PACLITAXEL NANOPARTICLE; LIPOSOME; LIPOSOME ENCAPSULATED ALBUMIN PACLITAXEL NANOPARTICLE; NANOPARTICLE; PACLITAXEL; UNCLASSIFIED DRUG; ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; LIPID; MACROGOL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER TISSUE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG RELEASE; DRUG STABILITY; ENCAPSULATION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL ENCAPSULATION; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; ULTRAFILTRATION; X RAY DIFFRACTION; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL SURVIVAL; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; EXPERIMENTAL MELANOMA; FEMALE; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; MCF 7 CELL LINE; MEDICINAL CHEMISTRY; METABOLISM; NANOMEDICINE; PARTICLE SIZE; PATHOLOGY; PHARMACEUTICS; PROCEDURES; SOLUBILITY; TISSUE DISTRIBUTION;

ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; LIPIDS; LIPOSOMES; MALE; MCF-7 CELLS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NANOMEDICINE; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; POLYETHYLENE GLYCOLS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; TISSUE DISTRIBUTION;

EID: 84923052766     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1512-2     Document Type: Article

References (46)

1. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990;82(15):1247-59.
2. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm. 2002;235(1):179-92.
3. Weiss RB, Donehower R, Wiernik P, Ohnuma T, Gralla R, Trump D, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8(7):1263-8.
4. Akhlaghi SP, Saremi S, Ostad SN, Dinarvand R, Atyabi F. Discriminated effects of thiolated chitosan-coated pMMA paclitaxel-loaded nanoparticles on different normal and cancer cell lines. Nanomedicine. 2010;6(5):689-97.
5. Bernabeu E, Helguera G, Legaspi MJ, Gonzalez L, Hocht C, Taira C, et al. Paclitaxel-loaded PCL-TPGS nanoparticles: In vitro and in vivo performance compared with Abraxane®. Colloids Surf B: Biointerfaces. 2014;113:43-50.
6. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590-8.
7. Fan T, Takayama K, Hattori Y, Maitani Y. Formulation optimization of paclitaxel carried by PEGylated emulsions based on artificial neural network. Pharm Res. 2004;21(9):1692-7.
8. Huh KM, Min HS, Lee SC, Lee HJ, Kim S, Park K. A new hydrotropic block copolymer micelle system for aqueous solubilization of paclitaxel. J Control Release. 2008;126(2):122-9.
9. Chen DB, Yang TZ, Lu WL, Zhang Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull. 2001;49(11):1444-7.
10. Wang X, Zhou J, Wang Y, Zhu Z, Lu Y, Wei Y, et al. A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. Eur J Cancer. 2010;46(8):1474-80.
11. Xiao K, Luo J, Fowler WL, Li Y, Lee JS, Xing L, et al. A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials. 2009;30(30):6006-16.
12. Xie Z, Guan H, Chen X, Lu C, Chen L, Hu X, et al. A novel polymer-paclitaxel conjugate based on amphiphilic triblock copolymer. J Control Release. 2007;117(2):210-6.
13. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7(8):1041-53.
14. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res. 2005;11(11):4136-43.
15. Devalapally H, Duan Z, Seiden MV, Amiji MM. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin Cancer Res. 2008;14(10):3193-203.
16. Koudelka S, Turanek J. Liposomal paclitaxel formulations. J Control Release. 2012;163(3):322-34.
17. Hyodo K, Yamamoto E, Suzuki T, Kikuchi H, Asano M, Ishihara H. Development of liposomal anticancer drugs. Biol Pharm Bull. 2013;36(5):703-7.
18. Ko YT, Falcao C, Torchilin VP. Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK) 2 and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy. Mol Pharm. 2009;6(3):971-7.
19. Ewe A, Schaper A, Barnert S, Schubert R, Temme A, Bakowsky U, et al. Storage stability of optimal liposome-polyethylenimine complexes (lipopolyplexes) for DNA or siRNA delivery. Acta Biomater. 2014;10(6):2663-73.
20. Liu M, Gan L, Chen L, Xu Z, Zhu D, Hao Z, et al. Supramolecular core-shell nanosilica@ liposome nanocapsules for drug delivery. Langmuir. 2012;28(29):10725-32.
21. Ko YT, Kale A, Hartner WC, Papahadjopoulos-Sternberg B, Torchilin VP. Self-assembling micelle-like nanoparticles based on phospholipid-polyethyleneimine conjugates for systemic gene delivery. J Control Release. 2009;133(2):132-8.
22. Miyata K, Christie RJ, Kataoka K. Polymeric micelles for nano-scale drug delivery. React Funct Polym. 2011;71(3):227-34.
23. Bansal A, Kapoor D, Kapil R, Chhabra N, Dhawan S. Design and development of paclitaxel-loaded bovine serum albumin nanoparticles for brain targeting. Acta Pharma. 2011;61(2):141-56.
24. Paal K, Muller J, Hegedus L. High affinity binding of paclitaxel to human serum albumin. Eur J Biochem. 2001;268(7):2187-91.
25. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst. 2006;98(5):335-44.
26. Trynda-Lemiesz L. Paclitaxel-HSA interaction. Binding sites on HSA molecule. Bioorg Med Chem. 2004;12(12):3269-75.
27. Trynda-Lemiesz L, Luczkowski M. Human serum albumin: spectroscopic studies of the paclitaxel binding and proximity relationships with cisplatin and adriamycin. J Inorg Biochem. 2004;98(11):1851-6.
28. Hiremath JG, Khamar NS, Palavalli SG, Rudani CG, Aitha R, Mura P. Paclitaxel loaded carrier based biodegradable polymeric implants: preparation and in vitro characterization. Saudi Pharm J. 2013;21(1):85-91.
29. Parveen S, Sahoo SK. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. Eur J Pharmacol. 2011;670(2):372-83.
30. Ernsting MJ, Murakami M, Undzys E, Aman A, Press B, Li SD. A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases. J Control Release. 2012;162(3):575-81.
31. Araki T, Kono Y, Ogawara KI, Watanabe T, Ono T, Kimura T, et al. Formulation and evaluation of paclitaxel-loaded polymeric nanoparticles composed of polyethylene glycol and polylactic acid block copolymer. Biol Pharm Bull. 2012;35(8):1306-13.
32. Ramasamy T, Tran TH, Cho HJ, Kim JH, Kim YI, Jeon JY, et al. Chitosan-based polyelectrolyte complexes as potential nanoparticulate carriers: physicochemical and biological characterization. Pharm Res. 2014;31(5):1302-14.
33. Raymond E, Hanauske A, Faivre S, Izbicka E, Clark G, Rowinsky EK, et al. Effects of prolonged versus short-term exposure paclitaxel (Taxol (R)) on human tumor colonyforming units. Anti Cancer Drugs. 1997;8(4):379-85.
34. Jiang L, Xu Y, Liu Q, Tang Y, Ge L, Zheng C, et al. A nontoxic disulfide bond reducing method for lipophilic drug-loaded albumin nanoparticle preparation: formation dynamics, influencing factors and formation mechanisms investigation. Int J Pharm. 2013;443(1):80-6.
35. Lee IH, Park YT, Roh K, Chung H, Kwon IC, Jeong SY. Stable paclitaxel formulations in oily contrast medium. J Control Release. 2005;102(2):415-25.
36. Zhang L, He Y, Ma G, Song C, Sun H. Paclitaxel-loaded polymeric micelles based on poly (ε-caprolactone)-poly (ethylene glycol)-poly (γ-caprolactone) triblock copolymers: in vitro and in vivo evaluation. Nanomedicine. 2012;8(6):925-34.
37. Ramasamy T, Kim J, Choi HG, Yong CS, Kim JO. Novel dual drug-loaded block ionomer complex micelles for enhancing the efficacy of chemotherapy treatments. J Biomed Nanotechnol. 2014;10(7):1304-12.
38. Zhu Z, Li Y, Li X, Li R, Jia Z, Liu B, et al. Paclitaxel-loaded poly (N-vinylpyrrolidone)- b-poly (ε-caprolactone) nanoparticles: preparation and antitumor activity in vivo. J Control Release. 2010;142(3):438-46.
39. Cho HJ, Yoon IS, Yoon HY, Koo H, Jin YJ, Ko SH, et al. Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin. Biomaterials. 2012;33(4):1190-200.
40. Termsarasab U, Cho HJ, Kim DH, Chong S, Chung SJ, Shim CK, et al. Chitosan oligosaccharide-arachidic acid-based nanoparticles for anti-cancer drug delivery. Int J Pharm. 2013;441(1):373-80.
41. Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, et al. Enhanced solubility and stability of PEGylated liposomal paclitaxel: In vitro and in vivo evaluation. Int J Pharm. 2007;338(1):317-26.
42. Zhang W, Shi Y, Chen Y, Yu S, Hao J, Luo J, et al. Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. Eur J Pharm Biopharm. 2010;75(3):341-53.
43. Ramasamy T, Kim JH, Choi JY, Tran TH, Choi HG, Yong CS, et al. pH sensitive polyelectrolyte complex micelles for highly effective combination chemotherapy. J Mater Chem B. 2014;2(37):6324-33.
44. Ko YT, Bhattacharya R, Bickel U. Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting. J Control Release. 2009;133(3):230-7.
45. Rowinsky E, Donehower R, editors. The clinical pharmacology of paclitaxel (Taxol). Semin Oncol. 1993;20(4-3):16-25.
46. Zhang C, Qu G, Sun Y, Wu X, Yao Z, Guo Q, et al. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl- O-sulfate chitosan micelles loaded with paclitaxel. Biomaterials. 2008;29(9):1233-41.